Dr. Thomas Carl Krivak, MD

Dr. Krivak practices at Allegheny General Hospital in Pittsburgh, Pennsylvania, part of Highmark Health.

Dr. Krivak's NPI, 1609840057, was assigned on February 14, 2006. Dr. Krivak graduated from Ohio State University College of Medicine in 1994. Dr. Krivak holds Pennsylvania license MD426420.

Dr. Krivak's primary practice is Allegheny General Hospital, at 320 East North Avenue, Pittsburgh, PA 15212 in Allegheny County. The practice phone is (412) 359-3131.

Dr. Krivak's primary practice is Allegheny General Hospital in Pittsburgh, Pennsylvania, part of Highmark Health. Dr. Krivak is also affiliated with West Penn Hospital. The medical group on file is AHN Primary Care - Family Med Associates at H+W Pavilion Bethel Park. Dmand AI also links Dr. Krivak to 4 more hospitals, 3 group practices and clinics, 2 medical groups and 1 breast imaging center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Krivak practices, 10 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Krivak's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Krivak is licensed in Pennsylvania.

CMS data shows 600 Medicare services from Dr. Krivak across 7 procedure codes in 2024, for 252 Medicare patients. Medicare paid $52,212 for them.

CMS counts 252 Medicare patients who saw Dr. Krivak in 2024. The largest group is 65 to 74, with 157 patients. 71% of them have high blood pressure, and 70% have high cholesterol. Their average risk score is 1.71, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Krivak's median patient age at 70, with 100% women.

In 2024, Dr. Krivak wrote 89 Medicare Part D claims for 41 patients. 99% of them were for generic drugs. CMS names the drug for 23 of them, across 1 drug with 11 or more claims each, at $495 in total drug cost. In 2023, CMS named 43 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Krivak for performance year 2024, reported through an alternative payment model (APM). Dr. Krivak accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 29 procedures of removal of the uterus by Dr. Krivak, more than 96% of the clinicians it reports for that procedure.

Dmand AI links 76 papers to Dr. Krivak, published from 2008 to 2024. 2015 was the busiest year, with 5. The most frequent topics are Ovarian Neoplasms, Carcinoma, Ovarian Epithelial and Antineoplastic Combined Chemotherapy Protocols. Dr. Krivak has published most often in Gynecol Oncol. Dr. Krivak's most frequent co-authors are Scott Daniel Richard, MD, Paniti Sukumvanich and Sushil Beriwal, MD.

Dmand AI links Dr. Krivak to 10 clinical trials, 4 of them phase 2/3 studies. 8 are still active or recruiting. Conditions studied include Fallopian Tube Diseases, Fallopian Tube Neoplasms and Carcinoma, Endometrioid. National Cancer Institute (NCI) sponsors the most, 6.

CMS Open Payments shows 1,769 general payments to Dr. Krivak from 36 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 72% of the total. AstraZeneca Pharmaceuticals LP paid the most, $797,025.

Dr. Krivak graduated from Ohio State University College of Medicine in 1994.